Selumetinib Shows Durable Tumour Shrinkage and Clinical Benefit in Neurofibromatosis
MEK inhibition is a rational treatment strategy for neurofibromatosis type 1–related tumours
Oncology News
ESMO oncology news aims to keep you up to date with the developments that affect you and your daily practice.
Make sure you check these pages frequently, or sign up to our newsletter! To sign up for ESMO newsletters, create a myESMO account here and select the newsletters you’d like to receive.
1549 results
Should Cancer Treatment Be Continued During the Pandemic? A Case-by-Case Discussion Is Required
With Florian Lordick, University Cancer Leipzig (UCCL), Germany
EMA Provides New Testing and Treatment Recommendations for Fluorouracil Capecitabine and Tegafur
Patients should be tested for DPD deficiency before starting treatment
Risk of Colorectal Cancer Incidence and Mortality After Polypectomy
Patients with sessile serrated polyps, tubulovillous adenomas, and villous adenomas might benefit from colonoscopy surveillance
EMA Starts Review of Ifosfamide to Examine Whether There is a Higher Risk of Encephalopathy
Studies suggest that the risk of encephalopathy is higher with the solution than with the powder form
Low Dose Aspirin Associated with a Lower Risk of Hepatocellular Carcinoma
Results of a study conducted among adults with chronic viral hepatitis in Sweden
EMA Recommends Granting Marketing Authorisation for Generic Azacitidine
Azacitidine betapharm and Azacitidine Mylan are generic of Vidaza, which has been authorised in the EU since 2008
FDA Grants Accelerated Approval to Nivolumab and Ipilimumab Combination for Hepatocellular Carcinoma
Evidence for efficacy is based on the results from the CHECKMATE-040 study
Systematic Viability Profiling of the Anticancer Potential of Non-Oncology Drugs
PRISM repurposing dataset represents nearly half of all drugs ever tested in humans
Use of Both, MRI-Targeted and 12-Core Systematic Biopsies in Prostate Cancer
Combined biopsy more effective in detection of prostate cancer
Withdrawal of Application to Change the Marketing Authorisation for Axumin
Intended extension of the use of fluciclovine (18F) was to include the detection and monitoring of glioma in adults using a PET scan
Withdrawal of Application to Change the EU Marketing Authorisation for Nivolumab and Ipilimumab
Intended extension of indication concerned metastatic non-small cell lung cancer that has not been previously treated